An open-label, multicenter, study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of three dosing regimens of oral AT2220 in patients with Pompe disease

Amicus Therapeutics, Inc.0 sites18 target enrollmentJanuary 7, 2009

Overview

No summary available.

Registry

who.int

Start Date

January 7, 2009

End Date

TBD

Last Updated

13 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

•1\. Male or female, 18 to 74 years of age at time of consent
•2\. Diagnosis of Pompe disease based on clinical assessment, enzyme assay, and/or genotyping. Confirmatory GAA genotyping will be performed on all subjects who are screened for the study.
•3\. Naïve to ERT or has not received ERT in the 3 months prior to screening
•4\. Willing not to initiate ERT or other prohibited treatment during study participation
•5\. Functional grade for arms and/or legs \=2 (See Appendix 2\) OR sitting FVC \= 30% and \< 80% of predicted value, with maximum FVC (L) value reproducible (± 15 % ) between Visits 1 and 2
•6\. Subjects of reproductive potential agree to use reliable methods of contraception during the study
•7\. Subject is willing and able to provide written informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes

•1\. Any intercurrent condition that may preclude accurate interpretation of study data
•2\. Obstructive pulmonary disease
•3\. Invasive ventilatory support
•4\. Use of noninvasive ventilatory support \> 8 hours a day while awake
•5\. History of QTc prolongation \> 450 msec for males and \> 470 msec for females
•6\. History of allergy or sensitivity to the study drug, including any prior serious adverse reaction to iminosugars (e.g., miglustat, miglitol)
•7\. Pregnancy or breast\-feeding
•8\. Current or recent drug or alcohol abuse
•9\. Treatment with another investigational drug within 30 days of study start
•10\. Use of prohibited medications \< 3 months prior to screening